News for InspireMD, Inc. (NSPR-WT)

MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Prime carotid stent system for the treatment of carotid artery di

**media[549752]**

MIAMI, Feb. 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Prime carotid stent system for the prevention of stroke, today an

On December 31, 2024, Nantahala Capital Management, LLC (Trades, Portfolio) made a significant move by increasing its stake in InspireMD Inc (NSPR). The firm ad

TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Prime Carotid Stent System for the prevention of

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) significantly increased its investment in InspireMD Inc. by acquiring an additional 7,419,918

**media[531558]**

MIAMI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Prime carotid stent system for the prevention of stroke, today an

InspireMD CFO Craig Shore to retire, successor search underway

MIAMI, Dec. 12, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Embolic Prevention Stent System (EPS) for the prevention of strok

**media[487010]**

Study represents a significant step forward in Company's mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solut

MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. ( NSPR), developer of the CGuardâ„¢ Embolic Prevention Stent System (EPS) for the prevention of strok

InspireMD, Inc. (NASDAQ:NSPR) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ETCompany ParticipantsChuck Padala - IR, Life AdvisorsMarvin...

InspireMD (NSPR) delivered earnings and revenue surprises of 20% and 4.02%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

InspireMD Inc (NSPR) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $1.74 million, and the earnings are e

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Embolic Protection...

The surge in demand for intracranial stents is predominantly driven by the growing occurrence of neurological conditions like intracranial stenosis and...